Relationship of IGF-1 and cardiac remodeling in overweight patients

Abstract

Objectives: To investigate the role of IGF-1 in the development of cardiac remodeling in patients with overweight and mild obesity.Materials and Methods: The study included 75 men (mean age 55.3 ± 6.3 years), which are overweight or have mild obesity (body mass index (BMI) 28.6 ± 3.6) without diabetes. Group 1 included 46 patients with normal weight and overweight (BMI 26.5 ± 3.6). Group 2 included 27 patients with obesity (mean BMI 32.4 ± 3.5). Coronary artery disease was confirmed by treadmill test and coronarography. All participants were evaluated by impaired glucose tolerance test (IGT), cholesterol, triglycerides (TG), IGF-1 and LPHD, and LPLD levels, geometry of the heart chambers by echocardiography.Results: Patients in both groups did not differ by age, blood pressure, percent of CAD and impaired glucose tolerance. IGF-1 levels were not significantly different among the study groups (210.1 and 216.6 ng/ml, p0.05). High circulating IGF-1 levels were frequently observed in Group 2 (in 50% and 25% patients, respectively; р=0.039). The concentric remodeling for patients with normal IGF-1 seen in 38% of patients compared to 52% in patients with high level of IGF-1. The eccentric hypertrophy for patients with normal IGF-1 was not observed compared to 16% in patients with high level of IGF-1. The concentric hypertrophy for patients with normal IGF-1 was 30.7% compared to 4% in patients with high level of IGF-1.Conclusions: IGF-1 has a significant effect on cardiac remodeling in patients with coronary artery disease and obesity. IGF-1 may be an important marker of prognosis of chronic heart failure in patients with obesity and an indicator of hypertension and associated cardiac remodeling.